INM Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 17:37):

Stats
Tagesvolumen	63 493.00
Durchschnittsvolumen	382 840
Marktkapitalisierung	1.42M
EPS	$0 ( 2024-02-16 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00300 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-14	Hull Andrew	Sell	42	Employee Stock Option (Expiration)
2024-03-04	Hsu Eric C	Sell	309	Employee Stock Option (Expiration)
2024-01-21	Mancini Alexandra Diane Janet	Sell	121	Employee Stock Option (Expiration)
2024-02-20	Jagpal Netta	Sell	50 000	Employee Stock Option (Right to Buy)
2024-02-21	Hull Andrew	Buy	37 500	Common Stock

INSIDER POWER
74.61
Last 93 transactions
Buy: 1 291 573 \| Sell: 391 310

Volumen Korrelation

Lang: -0.19 (neutral)

Kurz: -0.51 (weak negative)

Signal:(50.031) Neutral

InMed Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
ZSAN	0.901
KBSF	0.889
BNOX	0.885
ARQQ	0.884
AYLA	0.884
VIH	0.884
LYRA	0.882
QLGN	0.881
LQDT	0.879
DWACU	0.87

10 Am meisten negativ korreliert
STAY	-0.89
AVGO	-0.884
TIPT	-0.883
BNIXU	-0.876
TVTY	-0.875
ARDX	-0.874
USLM	-0.872
LRFC	-0.869
LUNA	-0.864
PEBK	-0.862

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

InMed Pharmaceuticals Korrelation - Währung/Rohstoff

0.00
( neutral )

0.37
( neutral )

0.00
( neutral )

-0.30
( neutral )

InMed Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$4.14M
Bruttogewinn:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2023
Umsatz:	$4.14M
Bruttogewinn:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2022
Umsatz:	$1.09M
Bruttogewinn:	$543 546 (49.89 %)
EPS:	$-41.74

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-38.00

Financial Reports:

No articles found.

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.